A-01 Registration at the conference venue Tuesday 09:30-17:30 |
A-02 Welcome reception with drinks and light snacks (no dinner) Tuesday 19:30-21:30 |
B-01 Registration at the conference venue Wednesday 08:00-08:45 |
B-04 Iain Gardner Pre-clinical and clinical applications of PBPK models for monoclonal antibodies and other large molecule modalities. Wednesday 09:00-09:45 |
B-05 Coffee break, Poster and Software Session I Wednesday 09:45-11:15 |
B-07 Hans Peter Grimm Learn-and-Confirm in Quantitative Systems Pharmacology: Evaluation of an Immunogenicity Platform Wednesday 11:15-11:35 |
B-08 Rory Leisegang Immunogenicity dynamics and covariate effects after satralizumab administration predicted with a Hidden Markov Model Wednesday 11:55-12:15 |
B-08 Alix Démaris Towards understanding anti-infliximab antibody development to predict Crohn’s disease patients' underlying immunogenicity status Wednesday 11:35-11:55 |
B-09 Lunch Wednesday 12:15-13:45 |
B-11 Xiaomei Chen Development of a tool for fully automatic model development (AMD) Wednesday 13:45-14:05 |
B-12 Marc Lavielle SAMBA: a new algorithm for automatic construction of nonlinear mixed-effects models. Wednesday 14:05-14:25 |
B-14 Ron Keizer Composite Importance Sampling (CIS) for continuous learning in precision dosing Wednesday 14:25-14:45 |
B-15 Benjamin Ribba Population model-enhanced reinforcement learning to enable precision dosing: case study with dosing of propofol for sedation Wednesday 14:45-15:05 |
B-16 Special Announcement Wednesday 15:05-15:10 |
B-17 Coffee break, Poster and Software Session II Wednesday 15:10-16:40 |
B-19 Orwa Albitar Pharmacometric Modeling of Drug Adverse Effects: An Application of Mixture Models in Schizophrenia Spectrum Disorder Patients Treated with Clozapine Wednesday 16:40-17:00 |
B-20 Jurgen Langenhorst An item response theory model with bounded integer subcomponents to describe the Mayo Clinic subscores in patients with ulcerative colitis Wednesday 17:00-17:20 |
C-02 Kamunkhwala Gausi A semi-mechanistic model of the population pharmacokinetics and bactericidal activity of high-dose isoniazid against multi-drug-resistant tuberculosis Thursday 08:30-08:55 |
C-03 Yu Fu A translational cardiovascular systems model to quantify drug effects on contractility and other hemodynamic variables Thursday 08:55-09:20 |
C-04 Soumya Perinparajah Mathematically Modelling CD19+ B Cell Reconstitution After Insult to the Immune System: Paediatric Allogeneic Haematopoietic Stem Cell Transplantation, Rituximab Therapy and Epstein-Barr Viral Reactivation Thursday 09:20-09:45 |
C-05 Presentation Lewis Sheiner Student Session Awards Thursday 09:45-09:50 |
C-06 Coffee break, Poster and Software session III Thursday 09:50-11:20 |
C-08 Marie Alexandre SARS-CoV-2 mechanistic correlates of protection in non-human primates: insight from modelling response to vaccines. Thursday 11:20-11:40 |
C-09 Alexandra Lavalley-Morelle Longitudinal biomarkers predicting death of hospitalized patients for SARS-COV-2 infection: a joint analysis with competing risks Thursday 11:40-12:00 |
C-10 Jacqueline Ernest Spatially and temporally resolved diffusion kinetics of bedaquiline and TBAJ-587 in hard-to-treat sites of TB disease Thursday 12:00-12:20 |
C-11 Federico Reali PBPK/PD modeling and machine learning approaches to support the development of new drugs and regimens against tuberculosis. Thursday 12:20-12:40 |
C-13 Lunch Thursday 12:45-14:15 |
C-15 Filippo Castiglione Modeling biology by agents Thursday 14:15-15:00 |
C-16 Coffee break, Poster, and Software Session IV Thursday 15:00-16:30 |
C-18 Sarah Baklouti A methodology to de-shrink Empirical Bayes Estimates Thursday 16:30-16:50 |
C-19 Thomas Bouillon Dose selection by covariate assessment on the optimal dose for efficacy – application of machine learning in the context of PKPD Thursday 16:50-17:10 |
C-20 Laura Zwep Copula modeling for realistic virtual patient covariate simulation Thursday 17:10-17:30 |
C-21 Social Event Thursday 20:00-00:00 |
D-02 Zinnia Parra-Guillen A physiologically-based pharmacokinetic/pharmacodynamic framework to support clinical development of V937, a novel oncolytic virus Friday 09:15-09:35 |
D-03 Marion Kerioui Joint modelling of individual target lesions and survival to characterize the variability in the response to immunotherapy versus chemotherapy in advanced bladder cancer Friday 09:35-09:55 |
D-04 Sebastien Benzekry Supporting decision making and early prediction of survival for oncology drug development using a pharmacometrics-machine learning based model. Friday 09:55-10:15 |
D-05 Sarah Lobet Target-response relationship of bevacizumab may be more relevant than exposure-response - a target-mediated drug disposition (TMDD) model Friday 10:15-0:35 |
D-06 Preview of PAGE 2023 Friday 10:35-10:40 |
D-07 Coffee break Friday 10:40-11:15 |
D-09 Perrine Courlet Modelling real-world tumor size dynamics based on electronic health records and image data in advanced melanoma patients receiving immunotherapy Friday 11:15-11:35 |
D-10 Luca Marzano Introducing a novel analytical framework for risk stratification of real-world data with survival and unsupervised machine learning. A small cell lung cancer SCLC study Friday 11:35-11:55 |